Regeneron Disrupts OTOF Gene Therapy Market with Free Access to FDA-Approved Otarmeni, Prompting Competitor Exits
Sensorion
Vestibular Dysfunction Treatment Drug Developer
RRGENER
Biopharmaceutical R&D Developer
otovio
Innovative Drug Developer
April 2026: Regeneron’s AAV Gene Therapy for DeafnessOtarmeniReceived FDA approval for market launch. Meanwhile, Regeneron reached an agreement with the U.S. government to provide it free of charge to American patients.Otarmeni。
And now, Regeneron is starting to dominate the competition with its “free supply” strategy.
# Leading CompetitorThe company has announced its withdrawal from the competition, which may continue to impact others subsequently.OTOF Gene Therapy Development Project.
Sensorion is aFrench biotechnology company, focused on developingInnovative therapies for the restoration, treatment, and prevention of hearing loss disorders. Its most advanced pipeline targetsAAV Gene Therapy for the OTOF GeneSENS-501（OTOF-GT）。
SENS-501 (OTOF-GT) is a dual-vector AAV gene therapy, developed bySensorion in 2019 within collaboration with the Pasteur Institute.SENS-501 is designed to leverage AAVDirectly deliver functional OTOF genes into hair cells to restoreOTOF-mediated hearing loss. Already obtainedEuropean Commission Orphan Drug Designation, and U.S. FDA Rare Pediatric Disease Designation and Orphan Drug Designation.
SENS-501 in June 2024 atThe first clinical trial was registered on ClinicalTrials.gov. In March 2026,Sensorion reportedSENS-501'sClinical TrialSix-Month Follow-Up Data: Early Efficacy Signals Persist, with Favorable Safety and Tolerability
However, with the firstThe Approval and Market Launch of OTOF Gene Therapy Drugs—The Emergence of Free Otarmeni Has Completely TransformedDevelopment and Market Environment of OTOF Gene Therapy
Sensorion, after review, decided to discontinuethe clinical development activities for SENS-501, shifting resources to focus on the GJB2 gene therapy SENS-601, which recentlyClinical trial applications were submitted in Canada and France, and the fast-track procedure was approved by the French agency (ANSM).
OTOF is one of the common genetic causes of auditory neuropathy. Statistics indicate that approximately 200,000 individuals worldwide suffer from OTOF-mediated hearing loss. This condition represents a market with significant potential, prompting multiple companies toOTOF AAV Gene Therapydevelopment.
IncludingRegeneron, itsOTOF AAV Gene TherapyOtarmeni has been successfully approved for marketing in the United States. Other competitors includeEli Lilly(Lilly in October 2022 atAcquired Akouos for $487 million, gaining OTOF gene therapyAK-OTOF）, as well as those who have already announced their withdrawal from the competitionSensorion；Several companies in China are also developingOTOF AAV, includingRRGENER、otovioetc.
Further Reading:Chinese Gene Therapy Restores Hearing in Five Deaf Children
However, with Regeneron'sOtarmeni successfully launched and is available free of charge in the United StatesThe OTOF hearing loss market will be completely dominated by Regeneron.
After losing the United States, the world's largest market for innovative drugs,With Sensorion decisively withdrawing, how will the other projects develop?
According to Eli Lilly’s first-quarter financial report released on April 30, 2026,AK-OTOF is still under continuous development. It is currently in Phase 1/2 clinical trials, with 22 patients enrolled, and the study is expected to be completed by October 2028.
while other overseasLimited information is available on the OTOF AAV project, but it is expected thatSensorion will not be the first to give up.
However, domesticallyThe OTOF AAV project is likely to be minimally impacted. As ChinaWith the continuous expansion of the innovative drug market and growing physician awareness of the clinical application of novel therapies such as cell and gene therapies, the market size for hearing loss gene therapy in China remains substantial. Furthermore, Chinese innovative pharmaceutical companies can extend their drug portfolios to neighboring countries in the Asia-Pacific region.
Click "Pharmadex" below”, follow for more exciting content
Disclaimer
WeChat Official Account push rules have changed yet again. If you don't click"Seen"or not set to"Starred", we might just fade into the vast sea of literature~ Click here to stay updated with the latest news from Pharmadl! ???